Akari chief executive David Horn Solomon has resigned following allegations of financial impropriety related to the personal use of a company credit card.
In a filing with the US financial regulator, the firm said that the resignation followed “an investigation conducted with the assistance of an independent law firm,” and that it “does not consider the amounts charged to be material to the company’s operations.”
Only a year ago former Akari CEO Gur Roshwalb was forced out of his position after irregularities related to clinical trial reporting came to light.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze